Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234372 | 1.00 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL8226797 | 1.00 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL3485952 | 1.00 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL711316 | 0.94 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL12088621 | 0.94 | GAA (0.53) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL711315 | 0.94 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL9892434 | 0.94 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL711824 | 0.94 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL12986573 | 0.93 | RAB9A (0.49) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL17189638 | 0.93 | GAA (0.49) | GAARAB9AALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-1984384-B1 | Conotoxin analogues, and methods for synthesis of intramolecular dicarba bridge containing peptides | SYNGENE LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-9035035-B2 | Macromolecular nucleotide compounds and methods for using the same | GENOVOXX GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8637650-B2 | Macromolecular nucleotide compounds and methods for using the same | GENOVOXX GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| EP-1984386-B1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LTD (AU) | 2013-10-09 | — | — | EP | disclosed |
| US-8552133-B2 | Controlled polymerisation process | SYNGENE LIMITED (AU) | 2013-10-08 | — | — | US | disclosed |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-8188217-B2 | — | — | 2012-05-29 | — | — | US | disclosed |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | MONASH UNIVERSITY (AU) | 2010-02-11 | — | — | US | disclosed |
| US-20100029494-A1 | Macromolecular Nucleotide Compounds And Methods For Using The Same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-1984385-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2008-10-29 | — | — | EP | disclosed |
| EP-1984384-A1 | CONOTOXIN ANALOGUES, AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE CONTAINING PEPTIDES | Monash University (AU) | 2008-10-29 | — | — | EP | disclosed |
| EP-1984386-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | Monash University (AU) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007093012-A1 | CONOTOXIN ANALOGUES, AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE CONTAINING PEPTIDES | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093013-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093014-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093014-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093013-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, CDCA2 | GAA 4501/4885RAB9A 2781/4885ALDH1A1 2184/4885 |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | DCLRE1A, RNF168, MTCL3 | GAA 4527/4885RAB9A 3002/4885ALDH1A1 2484/4885 |
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, MTCL3 | GAA 4527/4885RAB9A 3002/4885ALDH1A1 2484/4885 |
| US-20100029494-A1 | Macromolecular Nucleotide Compounds And Methods For Using The Same | DUT, SAMHD1, PNP | GAA 282/4885RAB9A 3244/4885ALDH1A1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.